The downregulated ALDH6A1 has been proved to regulate the immune response in clear cell renal cell carcinoma, which implied a new biomarker for the clinical immunotherapy of ccRCC patients [32]. Here, ALDH6A1 is linked to nonpapillary renal cell carcinoma.